



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Ad-Hoc Focus Group on RWD & RWE

Background, Objectives & Working Methods
04 July 2024

Patrice Verpillat
Real-World Evidence Workstream
Task Force Data Analytics & Methods


An agency of the European Union





RWD and RWE play a crucial role in bridging the gap between clinical research and practice


- Evidence generation is planned and guided by **purpose**, data, knowledge and expertise
- Research question drives evidence choice and embraces spectrum of data and methods
- **Clinical trials remain core but are bigger, better and faster**
- **Real world evidence is enabled, and its value is established**
- The patient voice guides every step of the way
- Healthcare systems are supported in their choices
- High levels of transparency underpin societal trust



At the core of a successful MA dossier
is excellent clinical evidence



Who delivers RWE for regulatory purpose in the EU?







EUROPEAN MEDICINES AGENCY
SCIENCE · MEDICINES · HEALTH

Medicines · Human regulatory · Veterinary regulatory · Committees · News & events · Partners & networks · About us ·

Home > News > DARWIN EU® continues expanding its capacity to deliver real-world data studies




DARWIN EU® continues expanding its capacity to deliver real-world data studies

Share

6 March 2024

The Data Analysis and Real World Interrogation Network DARWIN EU seeks ten new data partners in 2024.

News Human Data on medicines



EMA | RWD Catalogues

Home > Catalogue of RWD sources


Catalogue of RWD sources

(The catalogue also includes the data sources previously registered in the ENCaPP Resource Database)

Add a data source to the HMA-EMA Catalogue of real-world data sources

You need to log in with your EU Login account to register a data source.

[Discover how](#)



EMA | RWD Catalogues

Home > Catalogue of RWD studies

Catalogue of RWD studies

(The catalogue also includes the studies previously registered in the EU PAS Register(B))

Add a study to the HMA-EMA Catalogue of real-world data studies

You need to log in with your EU Login account to register a study.

[Discover how](#)



1 15 April 2024
2 EMA/150527/2024
3 Committee for Human Medicine Products/Methodology Working Party (CHMP/MWP)

4 Reflection paper on use of real-world data in non-
5 interventional studies to generate real-world evidence.

6 Draft

| | |
|---|---|
| Draft agreed by Methodology Working Party (MWP) | October 2023 |
| Adopted by CHMP PROM for release for consultation | 15 April 2024 |
| Start of public consultation | < DD Month YYYY> |
| End of consultation (deadline for comments) | < DD Month YYYY> |
| Agreed by Methodology Working Party (MWP) | <Month YYYY> |
| Adopted by CHMP PROM | < DD Month YYYY> |
| Comments should be provided using this EUSurvey form. For any technical issues, please contact the EUSurvey Support . | |
| Keywords | Non-interventional study, real-world data, real-world evidence, feasibility assessment, bias, confounding, data quality |

Willingness to intensified dialogue and continued collaboration on RWD/RWE



Overall objective of the proposed Ad-Hoc Focus Group

**Share knowledge and experience
with use of RWD and generation of RWE
to advance integration
of relevant and reliable RWE
in regulatory decision making**



Specific objectives

To **exchange views on RWD and RWE key concepts, discuss priorities and possible approaches, explore possible solutions** for enhancing the use of excellent evidence generated by the analysis of RWD into regulatory decision making

- The Focus Group should particularly discuss any relevant topics related to design of studies using RWD (e.g., data quality, fit-for-purpose data, feasibility assessment, place for innovative designs and/or methods...), interpretation and reporting of results (e.g., impact and interpretation of heterogeneity in multi-database studies...), and good science principles to be applied to any study using RWD (e.g., transparency, fit-for-purpose evidence...)
- The Focus Group could also identify RWD/RWE areas for multi-stakeholder approach needs, if relevant



Expected outcomes

- **Share views** on important concepts such as what is RWD and generated RWE, including “fit-for-purpose”
- **Reflect** on the application of the Data Quality Framework and use of the HMA-EMA RWD catalogues, and discuss ways for improvement if needed
- **Agree** on key elements to be assessed at the feasibility step of any study using RWD
- **Share experience** with novel/ innovative designs and methodologies
- ...



Working Method

Focus Group set-up now

Meetings will take place every 3 to 4 months (first meeting expected in Sep – TBC)

Call for topics to be sent 1 month before the planned meeting date

5 to 6 industry stakeholders experts participating per Focus Group meeting

(*Note:* Call for industry experts nominations with specific expert profile description (mostly be methodologists to fit the scientific/ technical discussions) will be sent by EMA to relevant EU Trade Associations)



We are committed to realize the full potential of RWE in regulatory decision making and we do recognize that the best science is advanced through dialogue, collaboration and trusted partnership



EUROPEAN MEDICINES AGENCY

Any questions?

Further information

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Telephone +31 (0)88 781 6000

Send us a question Go to www.ema.europa.eu/contact

Follow us on  **@EMA_News**

Classified as public by the European Medicines Agency